MLD type | Symptom status | Follow-up (years) | Atidarsagene | Standard care | Comparison between OTL and standard care | |||
---|---|---|---|---|---|---|---|---|
N | % GMFM-88 total score | N | % GMFM-88 total score | |||||
LI | Pre-symp | 2 | 11 | 73.1 | 9 | 7.6 | 65.6% (95% CI 48.9–82.3) | p < 0.001 in favour of Atidarsagene * |
LI | Pre-symp | 3 | 10 | 74.3 | 12 | 2.8 | 71.5% (95% CI 50.3–92.7) | p < 0.001 in favour of Atidarsagene* |
EJ | Mixed | 2 | 10 | 78.7 | 11 | 36.7 | 42.0% (95% CI 12.3–71.8) | p = 0.036 in favour of Atidarsagene* |
EJ | Mixed | 3 | 10 | 72.9 | 12 | 16.3 | 56.7% (95% CI 33.7%–79.6) | p < 0.001 in favour of Atidarsagene* |